Evidence map›Paper›PMID 24743323›Full record

ArticlePLoS genetics2014

Genetic predisposition to in situ and invasive lobular carcinoma of the breast.

Elinor Sawyer, Rebecca Roylance, Christos Petridis, Mark N Brook, Salpie Nowinski, Efterpi Papouli, Olivia Fletcher, Sarah Pinder, Andrew Hanby, Kelly Kohut and 144 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PLoS genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. The role of theAnnals of translational medicine · 2020
    Article
  9. Article
  10. Article
  11. Common Genetic Variation and Breast Cancer Risk-Past, Present, and Future.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Discriminatory power of common genetic variants in personalized breast cancer diagnosis.Proceedings of SPIE--the International Society for Optical Engineering · 2016
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

154 authors at 20 institutions in 17 countries.

Elinor SawyerResearch Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.
Rebecca RoylanceCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Christos PetridisResearch Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.
Mark N BrookDivision of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.
Salpie NowinskiResearch Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.
Efterpi PapouliBiomedical Research Centre, King's College London, Guy's Hospital, London, United Kingdom.
Olivia FletcherBreakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Sarah PinderResearch Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.
Andrew HanbyLeeds Institute of Molecular Medicine, St James's University Hospital, Leeds, United Kingdom.
Kelly KohutCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Patricia GormanCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Michele CaneppeleCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Julian PetoLondon School of Hygiene and Tropical Medicine, London, United Kingdom.
Isabel Dos Santos SilvaLondon School of Hygiene and Tropical Medicine, London, United Kingdom.
Nichola JohnsonBreakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Ruth SwannDepartment of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.
Miriam DwekDepartment of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.
Katherine-Anne PerkinsDepartment of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.
Cheryl GillettResearch Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.
Richard HoulstonDivision of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.
Gillian RossThe Royal Marsden NHS Foundation Trust, London, United Kingdom.
Paolo De IesoThe Royal Marsden NHS Foundation Trust, London, United Kingdom.
Melissa C SoutheyDepartment of Pathology, The University of Melbourne, Melbourne, Australia.
John L HopperCentre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.
Elena ProvenzanoNIHR Cambridge Biomedical Research Centre, Addenbrookes Hospital, Cambridge, United Kingdom.
Carmel ApicellaCentre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.
Jelle WesselingNetherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Sten CornelissenNetherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Renske KeemanNetherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Peter A FaschingDavid Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, California, United States of America; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Sebastian M JudDepartment of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Arif B EkiciInstitute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Matthias W BeckmannDepartment of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Michael J KerinSurgery, Clinical Science Institute, National University of Ireland, Galway, Ireland.
Federick MarmeDepartment of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.
Andreas SchneeweissDepartment of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.
Christof SohnDepartment of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.
Barbara BurwinkelDepartment of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; Molecular Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Pascal GuénelInserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer, Villejuif, France; University Paris-Sud, UMRS 1018, Villejuif, France.
Therese TruongInserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer, Villejuif, France; University Paris-Sud, UMRS 1018, Villejuif, France.
Pierre Laurent-PuigUniversité Paris Sorbonne Cité, UMR-S775 Inserm, Paris, France.
Pierre KerbratCentre Eugène Marquis, Department of Medical Oncology, Rennes, France.
Stig E BojesenCopenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.
Børge G NordestgaardCopenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.
Sune F NielsenCopenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.
Henrik FlygerDepartment of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
Roger L MilneGenetic & Molecular Epidemiology Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.
Jose Ignacio Arias PerezServicio de Cirugía General y Especialidades, Hospital Monte Naranco, Oviedo, Spain.
Primitiva MenéndezServicio de Anatomía Patológica, Hospital Monte Naranco, Oviedo, Spain.
Javier BenitezHuman Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Aida Karina DieffenbachDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Volker ArndtDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Christa StegmaierSaarland Cancer Registry, Saarbrücken, Germany.
Alfons MeindlDivision of Gynaecology and Obstetrics, Technische Universität München, Munich, Germany.
Peter LichtnerInstitute of Human Genetics, Technische Universität, Munich, Germany.
Rita K SchmutzlerCentre for Familial Breast and Ovarian Cancer and Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Magdalena LochmannDivision of Gynaecology and Obstetrics, Technische Universität München, Munich, Germany.
Hiltrud BrauchDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany.
Hans-Peter FischerInstitute of Pathology, Medical Faculty of the University of Bonn, Bonn, Germany.
Yon-Dschun KoDepartment of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany.
GENICA Network
Heli NevanlinnaDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
Taru A MuranenDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
Kristiina AittomäkiDepartment of Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland.
Carl BlomqvistDepartment of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Natalia V BogdanovaDepartment of Radiation Oncology, Hannover Medical School, Hannover, Germany.
Thilo DörkGynaecology Research Unit, Hannover Medical School, Hannover, Germany.
Annika LindblomDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Sara MargolinDepartment of Oncology - Pathology, Karolinska Institutet, Stockholm, Sweden.
Arto MannermaaSchool of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.
Vesa KatajaSchool of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.
Veli-Matti KosmaSchool of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.
Jaana M HartikainenSchool of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.
Georgia Chenevix-TrenchDepartment of Genetics, QIMR Berghofer Institute of Medical Research, Brisbane, Australia.
KConFab InvestigatorsPeter MacCallum Cancer Center, Melbourne, Australia.
Diether LambrechtsVesalius Research Center (VRC), VIB, Leuven, Belgium; Department of Oncology, University of Leuven, Leuven, Belgium.
Caroline WeltensUniversity Hospital Gashuisberg, Leuven, Belgium.
Erik Van LimbergenUniversity Hospital Gashuisberg, Leuven, Belgium.
Sigrid HatseUniversity Hospital Gashuisberg, Leuven, Belgium.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Anja RudolphDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Petra SeiboldDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Dieter Flesch-JanysDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Paolo RadiceUnit of Molecular Bases of Genetic Risk and Genetic Testing, Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy; IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy.
Paolo PeterlongoIFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy.
Bernardo BonanniDivision of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO), Milan, Italy.
Sara VolorioIFOM, Fondazione Istituto FIRC di Oncologia Molecolare and Cogentech Cancer Genetic Test Laboratory, Milan, Italy.
Graham G GilesCancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.
Gianluca SeveriCancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.
Laura BagliettoCancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.
Catriona A McLeanDepartment of Pathology, The Alfred Hospital, Prahran, Victoria, Australia.
Christopher A HaimanDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.
Brian E HendersonDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.
Fredrick SchumacherDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.
Loic Le MarchandEpidemiology Program, Cancer Research Center, University of Hawaii, Honolulu, Hawaii, United States of America.
Jacques SimardCancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Laval University, Quebec, Canada.
Mark S GoldbergDepartment of Medicine, McGill University, Montreal, Quebec, Canada; Division of Clinical Epidemiology, McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec, Canada.
France LabrècheDépartement de médecine sociale et préventive, Département de santé environnementale et santé au travail, Université de Montréal, Montreal, Quebec, Canada.
Martine DumontCancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Laval University, Quebec, Canada.
Vessela KristensenDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway; Faculty of Medicine (Faculty Division Ahus), UiO, Oslo, Norway.
Robert WinqvistLaboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter Oulu, University of Oulu, NordLab/Oulu University Hospital, Oulu, Finland.
Katri PylkäsLaboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter Oulu, University of Oulu, NordLab/Oulu University Hospital, Oulu, Finland.
Arja Jukkola-VuorinenDepartment of Oncology, Oulu University Hospital, University of Oulu, Oulu, Finland.
Saila KauppilaDepartment of Oncology, Oulu University Hospital, University of Oulu, Oulu, Finland.
Irene L AndrulisOntario Cancer Genetics Network, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Julia A KnightSamuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Gord GlendonOntario Cancer Genetics Network, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Anna Marie MulliganLaboratory Medicine Program, University Health Network, Toronto, Ontario; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Peter DevilleeDepartment of Human Genetics & Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Rob A E M TollenaarDepartment of Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Caroline M SeynaeveFamily Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Mieke KriegeFamily Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Jonine FigueroaDivision of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.
Stephen J ChanockDivision of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.
Mark E ShermanDivision of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.
Maartje J HooningDepartment of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Antoinette HollestelleDepartment of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Ans M W van den OuwelandDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.
Carolien H M van DeurzenDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Jingmei LiHuman Genetics Division, Genome Institute of Singapore, Singapore.
Kamila CzeneMedical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Keith HumphreysMedical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Angela CoxCRUK/YCR Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield, United Kingdom.
Simon S CrossAcademic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, United Kingdom.
Malcolm W R ReedCRUK/YCR Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield, United Kingdom.
Mitul ShahCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
Anna JakubowskaDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Jan LubinskiDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Katarzyna Jaworska-BieniekDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland; Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland.
Katarzyna DurdaDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Anthony SwerdlowDivision of Genetics and Epidemiology and Division of Breast Cancer Research, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.
Alan AshworthBreakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom.
Nicholas OrrBreakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom.
Minouk SchoemakerDivision of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.
Fergus J CouchDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America.
Emily HallbergDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.
Anna González-NeiraHuman Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.
Guillermo PitaHuman Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.
M Rosario AlonsoHuman Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.
Daniel C TessierMcGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.
Daniel VincentMcGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.
Francois BacotMcGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.
Manjeet K BollaCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Qin WangCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Joe DennisCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Kyriaki MichailidouCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Alison M DunningCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
Per HallMedical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Doug EastonCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Paul PharoahCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Marjanka K SchmidtNetherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Ian TomlinsonWellcome Trust Centre for Human Genetics and Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.
Montserrat Garcia-ClosasDivision of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom; Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
University of Cambridge · GBGerman Cancer Research Center · DEInstitute of Cancer Research · GBGuy's Hospital · GBSpanish National Cancer Research Centre · ESThe University of Melbourne · AUNational Cancer Institute · USUniversity of Eastern Finland · FIUniversity of Southern California · USErasmus MC · NLKarolinska Institutet · SEMount Sinai Hospital · CAQueen Mary University of London · GBFriedrich-Alexander-Universität Erlangen-Nürnberg · DEHeidelberg University · DEOulu University Hospital · FIThe Netherlands Cancer Institute · NLUniversitair Ziekenhuis Leuven · BEUniversity of Copenhagen · DKUniversity of Helsinki · FI

Funding

Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
GENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTSR01CA063464 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2001 to 2005
$23.2M
Multiethnic Cohort Study of Diet and CancerR37CA054281 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 2003 to 2012
$23.2M
Northern California Cooperative Family Registry for Breast CancerU01CA069417 · NCI · NORTHERN CALIFORNIA CANCER CENTER · PI JOHN, ESTHER M. · 1995 to 2010
$22.4M
Breast Cancer Family Registry CohortUM1CA164920 · NCI · CANCER PREVENTION INSTIT OF CALIFORNIA · PI ANDRULIS, IRENE, BUYS, SAUNDRA S · 2012 to 2017
$12.7M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098758 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2003 to 2010
$11.0M
ONTARIO REGISTRY FOR STUDIES OF FAMILIAL BREAST CANCERU01CA069467 · NCI · CANCER CARE ONTARIO · PI ANDRULIS, IRENE L. · 1995 to 2010
$10.4M
THE AUSTRALIAN BREAST CANCER FAMILY REGISTRYU01CA069638 · NCI · UNIVERSITY OF MELBOURNE · PI HOPPER, JOHN L · 1995 to 2010
$6.6M
A genome-wide association study for breast cancer in BRCA1 mutation carriersR01CA128978 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH · 2008 to 2012
$4.8M
MULTIETHNIC/MINORITY COHORT STUDY OF DIET AND CANCERR01CA054281 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 1993 to 2002
$4.5M
Fine-mapping of 8q24 and Loci Identified in Genome-Wide Studies for Breast & ColoR01CA132839 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HAIMAN, CHRISTOPHER ALAN · 2008 to 2010
$2.0M
Breast Cancer Now 2010NOVPR61Cancer Research UK 10124Cancer Research UK 16459Cancer Research UK 16561Cancer Research UK 16563Cancer Research UK 16565Cancer Research UK C1287/A10118Cancer Research UK C1287/A12014Cancer Research UK C490/A10124NCI NIH HHS CA098758NCI NIH HHS CA132839NCI NIH HHS CA54281NCI NIH HHS CA63464NCI NIH HHS P50 CA116201NCI NIH HHS R01 CA054281NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA128978NCI NIH HHS R01 CA132839NCI NIH HHS R37 CA054281NCI NIH HHS U01 CA063464NCI NIH HHS U01 CA069417NCI NIH HHS U01 CA069467NCI NIH HHS U01 CA069638NCI NIH HHS U01 CA098758NCI NIH HHS U01 CA69417NCI NIH HHS U01 CA69467NCI NIH HHS U01 CA69638NCI NIH HHS UM1 CA164920Wellcome Trust 090532Wellcome Trust 090532/Z/09/Z
6 · The paper itself

Abstract

Invasive lobular breast cancer (ILC) accounts for 10-15% of all invasive breast carcinomas. It is generally ER positive (ER+) and often associated with lobular carcinoma in situ (LCIS). Genome-wide association studies have identified more than 70 common polymorphisms that predispose to breast cancer, but these studies included predominantly ductal (IDC) carcinomas. To identify novel common polymorphisms that predispose to ILC and LCIS, we pooled data from 6,023 cases (5,622 ILC, 401 pure LCIS) and 34,271 controls from 36 studies genotyped using the iCOGS chip. Six novel SNPs most strongly associated with ILC/LCIS in the pooled analysis were genotyped in a further 516 lobular cases (482 ILC, 36 LCIS) and 1,467 controls. These analyses identified a lobular-specific SNP at 7q34 (rs11977670, OR (95%CI) for ILC = 1.13 (1.09-1.18), P = 6.0 × 10(-10); P-het for ILC vs IDC ER+ tumors = 1.8 × 10(-4)). Of the 75 known breast cancer polymorphisms that were genotyped, 56 were associated with ILC and 15 with LCIS at P<0.05. Two SNPs showed significantly stronger associations for ILC than LCIS (rs2981579/10q26/FGFR2, P-het = 0.04 and rs889312/5q11/MAP3K1, P-het = 0.03); and two showed stronger associations for LCIS than ILC (rs6678914/1q32/LGR6, P-het = 0.001 and rs1752911/6q14, P-het = 0.04). In addition, seven of the 75 known loci showed significant differences between ER+ tumors with IDC and ILC histology, three of these showing stronger associations for ILC (rs11249433/1p11, rs2981579/10q26/FGFR2 and rs10995190/10q21/ZNF365) and four associated only with IDC (5p12/rs10941679; rs2588809/14q24/RAD51L1, rs6472903/8q21 and rs1550623/2q31/CDCA7). In conclusion, we have identified one novel lobular breast cancer specific predisposition polymorphism at 7q34, and shown for the first time that common breast cancer polymorphisms predispose to LCIS. We have shown that many of the ER+ breast cancer predisposition loci also predispose to ILC, although there is some heterogeneity between ER+ lobular and ER+ IDC tumors. These data provide evidence for overlapping, but distinct etiological pathways within ER+ breast cancer between morphological subtypes.

Indexed as

Breast NeoplasmsCarcinoma in SituCarcinoma, LobularCase-Control StudiesFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansMiddle AgedPolymorphism, Single Nucleotide

Identifiers

PMID24743323
PMCPMC3990493
OpenAlexW2163037142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.